公开(公告)号：US20090117658A1

公开(公告)日：2009-05-07

申请号：US12149097

申请日：2008-04-25

Applicant: Thomas E. Wagner ,  Gunter Schwamberger ,  Xianzhong Yu

Inventor： Thomas E. Wagner ,  Gunter Schwamberger ,  Xianzhong Yu

IPC: C12N15/86 ,  C12N15/06 ,  C12N15/64

CPC classification number: A61K47/6927 ,  A61K47/61 ,  A61K47/6901 ,  C12N2799/022 ,  C12N2810/10

Abstract: Described are a method and a composition for transfecting monocytes, as well as use of the same for therapeutic purposes. The composition is composed of a nucleic acid component, a lysosome evading component and a digestible particle that can be phagocytized. Preferably, the monocyte is a macrophage and the digestible particle is from a natural source, such as from a microbial source. More preferably, the digestible particle is a yeast cell wall particle such as zymosan. The composition itself, or cells pretreated with the composition, are useful in all gene medicine applications, such as gene therapy, gene vaccination, cancer treatment as well as immunomodulation and tissue repair.

Abstract translation: 描述了用于转染单核细胞的方法和组合物，以及将其用于治疗目的。 该组合物由核酸组分，溶酶体逃避组分和可以吞噬的可消化颗粒组成。 优选地，单核细胞是巨噬细胞，并且可消化颗粒来自天然来源，例如来自微生物来源。 更优选地，可消化颗粒是酵母细胞壁颗粒如酵母聚糖。 组合物本身或用组合物预处理的细胞可用于所有基因医学应用，例如基因治疗，基因疫苗接种，癌症治疗以及免疫调节和组织修复。

公开(公告)号：US07550426B2

公开(公告)日：2009-06-23

申请号：US11131443

申请日：2005-05-18

Applicant: Thomas E. Wagner ,  Xianzhong Yu

Inventor： Thomas E. Wagner ,  Xianzhong Yu

IPC: A61K38/16 ,  A61K38/33 ,  A61K45/00 ,  C07K14/195 ,  C07K14/435

CPC classification number: C07K14/195 ,  A61K38/00 ,  C07K14/44 ,  Y02A50/471 ,  Y10S530/82 ,  Y10S530/822 ,  Y10S530/823 ,  Y10S530/825

Abstract: A class of procytotoxic agents is characterized by a capability to kill with target cell-specificity. Such an aspect can be a pore-forming protein which has at least one lysine residue, modified by a peptide linkage to an amino acid residue, via the epsilon amino group, and an acetyl group. These agents are useful in treating cancer, especially prostate cancer.

Abstract translation: 一类原细胞毒素的特征在于具有靶细胞特异性的杀死能力。 这样的一个方面可以是具有至少一个赖氨酸残基的成孔蛋白，其通过与氨基酸残基的肽键经由ε氨基和乙酰基修饰。 这些药剂可用于治疗癌症，特别是前列腺癌。

公开(公告)号：US20090081789A1

公开(公告)日：2009-03-26

申请号：US12149086

申请日：2008-04-25

Applicant: Thomas E. Wagner ,  Gunter Schwamberger ,  Xianzhong Yu ,  Yanzhang Wei

Inventor： Thomas E. Wagner ,  Gunter Schwamberger ,  Xianzhong Yu ,  Yanzhang Wei

IPC: C12N5/02

CPC classification number: C12N15/113 ,  A61K47/6901 ,  A61K47/6923 ,  C12N2310/11 ,  C12N2310/111 ,  C12N2310/53 ,  C12N2799/022

Abstract: The present invention describes a method for targeting a tumor cell comprising contacting the tumor cell with a composition comprising a macrophage and a factor that upregulates nuclear factor-kappa B (NFκB) activity.

Abstract translation: 本发明描述了靶向肿瘤细胞的方法，包括使肿瘤细胞与包含巨噬细胞的组合物和上调核因子κB（NFκB）活性的因子接触。

公开(公告)号：US07425535B2

公开(公告)日：2008-09-16

申请号：US11123182

申请日：2005-05-06

Applicant: Xianzhong Yu ,  Thomas E. Wagner

Inventor： Xianzhong Yu ,  Thomas E. Wagner

IPC: A61K38/16 ,  A61K38/33 ,  A61K45/00 ,  C07K14/195 ,  C07K14/435

CPC classification number: C07K14/44 ,  A61K38/00 ,  A61K39/00 ,  A61K47/65 ,  C07K14/43563 ,  C07K14/43572 ,  C07K16/18 ,  Y02A50/472 ,  Y10S530/82 ,  Y10S530/822 ,  Y10S530/823 ,  Y10S530/825

Abstract: A class of procytotoxic agents is characterized by a capability to kill with target cell-specificity. Such an aspect can be a pore-forming protein which has at least one lysine residue, modified by a peptide linkage to an amino acid residue, via the epsilon amino group. These agents are useful in treating cancer, especially prostate cancer.

Abstract translation: 一类原细胞毒素的特征在于具有靶细胞特异性的杀死能力。 这样的一个方面可以是通过ε氨基具有至少一个被氨基酸残基的肽连接修饰的赖氨酸残基的成孔蛋白质。 这些药剂可用于治疗癌症，特别是前列腺癌。

公开(公告)号：US20130131640A1

公开(公告)日：2013-05-23

申请号：US13697166

申请日：2011-05-09

Applicant: Thomas E. Wagner ,  Yanzhang Wei ,  Jinhua Li Wei

Inventor： Thomas E. Wagner ,  Yanzhang Wei ,  Jinhua Li Wei

IPC: C12N5/16

CPC classification number: C12N5/16 ,  A61K39/0011 ,  A61K2035/124 ,  A61K2039/5152 ,  A61K2039/5154

Abstract: An efficient and simplified method for preparing and sorting fused cells is described herein. This approach yields fused cells useful in a variety of applications, including clinical treatment regimens, as cellular modulators of the immune system.

Abstract translation: 本文描述了用于制备和分选融合细胞的有效和简化的方法。 该方法产生可用于各种应用的融合细胞，包括临床治疗方案，作为免疫系统的细胞调节剂。

公开(公告)号：US20100111985A1

公开(公告)日：2010-05-06

申请号：US12610964

申请日：2009-11-02

Applicant: Gunter SCHWAMBERGER ,  Thomas E. Wagner

Inventor： Gunter SCHWAMBERGER ,  Thomas E. Wagner

IPC: A61K39/00 ,  A61P37/04

CPC classification number: A61K39/39 ,  A61K47/646 ,  A61K2039/55555 ,  A61K2039/6087 ,  A61K2039/64

Abstract: Described are a method and a composition for delivery of a protein to an antigen presenting cell. The composition is composed of a polypeptide component, a buffering component and a particle to be phagocytized. In one embodiment, the antigen presenting cell is aa macrophage or a dendritic cell and the particle to be phagocytized is from a natural source, such as from a microbial source. The composition itself, or cells pretreated with the composition, are useful for strategies in vaccine development.

Abstract translation: 描述了将蛋白质递送至抗原呈递细胞的方法和组合物。 该组合物由多肽组分，缓冲组分和待吞噬的颗粒组成。 在一个实施方案中，抗原呈递细胞是巨噬细胞或树突状细胞，并且被吞噬的颗粒来自天然来源，例如来自微生物源。 组合物本身或用组合物预处理的细胞可用于疫苗开发中的策略。

公开(公告)号：US20100047288A1

公开(公告)日：2010-02-25

申请号：US12461760

申请日：2009-08-24

Applicant: Thomas E. Wagner ,  Yanzhang Wei

Inventor： Thomas E. Wagner ,  Yanzhang Wei

IPC: A61K39/00 ,  C12N5/00 ,  A61K35/12 ,  A61P35/00 ,  A61P37/06

CPC classification number: A61K39/0011 ,  A61K35/13 ,  A61K35/15 ,  A61K35/74 ,  A61K39/0008 ,  A61K2035/122 ,  A61K2039/5152 ,  A61K2039/5154 ,  A61K2039/545 ,  A61K2039/55594 ,  C12N5/16 ,  C12N5/163 ,  A61K2300/00

Abstract: The present invention relates to cancer treatment compositions and methods for treating a specific cancer patient population. In particular, the application describes methods of treating a patient with cancer, such as a neuroblastoma, with a hybrid cell preparation.

Abstract translation: 本发明涉及用于治疗特定癌症患者群体的癌症治疗组合物和方法。 特别地，本申请描述了用混合细胞制剂治疗患有癌症的患者，例如神经母细胞瘤的方法。

公开(公告)号：US07201905B2

公开(公告)日：2007-04-10

申请号：US09815306

申请日：2001-03-23

Applicant: Wen Y. Chen ,  Thomas E. Wagner

Inventor： Wen Y. Chen ,  Thomas E. Wagner

IPC: A61K39/00

CPC classification number: C12N15/62 ,  A61K38/00 ,  C07K14/55 ,  C07K14/57554 ,  C07K2319/00 ,  C07K2319/74 ,  C07K2319/75

Abstract: A novel fusion protein, comprising a receptor-antagonizing domain and a positive immunomodulator domain, characterized, for example, by its ability to block apoptosis and/or inhibit endocrine response, is useful in treating cancer. For example, a human prolactin antagonist-interleukin 2 (hPRLA-IL-2) fusion protein combines apoptosis induction and immuno-therapy to combat cancer in the breast or prostate.

Abstract translation: 包含受体拮抗结构域和阳性免疫调节结构域的新型融合蛋白，其特征在于例如通过其阻断凋亡和/或抑制内分泌反应的能力，可用于治疗癌症。 例如，人类催乳素拮抗剂 - 白细胞介素2（hPRLA-IL-2）融合蛋白将凋亡诱导和免疫治疗结合起来以对抗乳腺或前列腺癌。

公开(公告)号：US06849451B2

公开(公告)日：2005-02-01

申请号：US09756293

申请日：2001-01-09

Applicant: Thomas E. Wagner ,  Yanzhang Wei

Inventor： Thomas E. Wagner ,  Yanzhang Wei

IPC: C12N15/02 ,  A61K35/12 ,  A61K35/13 ,  A61K35/14 ,  A61K35/15 ,  A61K38/00 ,  A61K39/00 ,  A61P3/10 ,  A61P31/00 ,  A61P31/04 ,  A61P31/10 ,  A61P33/00 ,  A61P33/02 ,  A61P33/04 ,  A61P33/10 ,  A61P35/00 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  A61P43/00 ,  C12N5/02 ,  C12N5/06 ,  C12N5/10 ,  C12N5/16 ,  C12N5/12 ,  A01N65/00 ,  A01N33/48 ,  A01N21/75 ,  A01N21/76

CPC classification number: A61K35/15 ,  A61K35/13 ,  A61K38/2013 ,  A61K39/0011 ,  A61K2039/5152 ,  A61K2039/5154 ,  C12N5/16 ,  C12N5/163 ,  A61K2300/00

Abstract: A rapid, simple-to-use method for preparing hybrid cells, applicable to fully differentiate, non-dividing cells, entails bringing at least two different cells into contact under conditions that promote cell fusion and then purifying the resultant hybrid without antibiotic or metabolic selection. This approach yields hybrid cells useful in a variety of applications, including clinical treatment regimens, as cellular modulators of the immune system.

Abstract translation: 用于制备适用于完全分化非分裂细胞的杂交细胞的快速，简单易用的方法需要在促进细胞融合的条件下使至少两种不同的细胞接触，然后在没有抗生素或代谢选择的情况下纯化所得杂交体 。 该方法产生可用于各种应用的混合细胞，包括临床治疗方案，作为免疫系统的细胞调节剂。

公开(公告)号：US06254497B1

公开(公告)日：2001-07-03

申请号：US09293224

申请日：1999-04-16

Applicant: Marion T. Brant ,  Thomas E. Wagner ,  Ernest D. Siders

Inventor： Marion T. Brant ,  Thomas E. Wagner ,  Ernest D. Siders

IPC: A63B5700

CPC classification number: A63B47/02 ,  A63B57/0037 ,  A63B57/207 ,  A63B57/353 ,  A63B2225/055

Abstract: A method and apparatus for setting a golf ball and a golf tee and for managing a golf ball on the green, without squatting or bending to the ground is provided. The apparatus contains a shaft having a setting end and a ball handling end. The setting end is adapted to releasably hold a golf ball and a golf tee and that selectively releases a golf ball onto a golf tee and inserts the golf tee into the turf. The ball handling end is adapted to pick up a golf ball or marker and includes a ball ejector. Preferably the device contains supports to allow the device to be self-standing and the supports contain a slot into which a golf tee may be inserted for removal from the turf after use.

Abstract translation: 提供了一种用于设置高尔夫球和高尔夫球座的方法和装置，并且用于管理绿色的高尔夫球，而不会蹲下或弯曲到地面。 该装置包括具有设定端和球处理端的轴。 设置端适于可释放地保持高尔夫球和高尔夫球座，并且选择性地将高尔夫球释放到高尔夫球座上，并将高尔夫球座插入草皮中。 球处理端适于拾取高尔夫球或标记并且包括球喷射器。 优选地，该装置包括允许装置自立的支撑件，并且支撑件包含可以插入高尔夫球座的槽，用于在使用后从草皮中取出。